Metabolic syndrome: An important risk factor for Parkinson's disease

Oxidative Medicine and Cellular Longevity

Volumn 2014, Issue , 2014, Pages

  Zhang, Pei ^a,b   Tian, Bo ^a,b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

NEURODEGENERATIVE DISEASES;

CARDIO-VASCULAR DISEASE; METABOLIC SYNDROMES; PARKINSON'S DISEASE; RISK FACTORS;

METABOLISM;

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CAFFEINE; CANNABINOID; CASPASE 3; DNA; ESTRADIOL; FAT; GLUCOSE; HOMOCYSTEINE; HYDROGEN; INSULIN; OXIDOPAMINE; PHYTOESTROGEN; PLANT EXTRACT; POLYPHENOL DERIVATIVE; QUERCETIN; REACTIVE OXYGEN METABOLITE; RESVERATROL; SESAMIN; SUPEROXIDE; URIC ACID; VITAMIN D;

ALZHEIMER DISEASE; APOPTOSIS; BODY FAT; CINNAMON; COFFEE; CYTOKINE PRODUCTION; DAILY LIFE ACTIVITY; DETOXIFICATION; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DNA DAMAGE; DOPAMINERGIC TRANSMISSION; ENDOPLASMIC RETICULUM STRESS; ENDOTHELIAL DYSFUNCTION; EXERCISE; GENETIC SUSCEPTIBILITY; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; INFLAMMATION; INSULIN RESISTANCE; LIFE EXPECTANCY; LIPID DIET; LIPID METABOLISM; METABOLIC SYNDROME X; MICROGLIA; NITROSATIVE STRESS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PHYSICAL ACTIVITY; REVIEW; RISK FACTOR; RISK REDUCTION; SKINFOLD THICKNESS; SUBSTANTIA NIGRA; VITAMIN SUPPLEMENTATION; COMPLICATION; MOLECULARLY TARGETED THERAPY; OXIDATION REDUCTION REACTION; PATHOLOGY;

HOMEOSTASIS; HUMANS; METABOLIC SYNDROME X; MOLECULAR TARGETED THERAPY; OXIDATION-REDUCTION; PARKINSON DISEASE; RISK FACTORS;

EID: 84901936702     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2014/729194     Document Type: Review

References (102)

1. Mokdad A. H., Serdula M. K., Dietz W. H., Bowman B. A., Marks J. S., Koplan J. P., The spread of the obesity epidemic in the United States, 1991-1998. Journal of the American Medical Association 1999 282 16 1519 1522 2-s2.0-0032697493 10.1001/jama.282.16.1519 (Pubitemid 29504044)
2. Abbott R. D., Ross G. W., White L. R., Nelson J. S., Masaki K. H., Tanner C. M., Curb J. D., Blanchette P. L., Popper J. S., Petrovitch H., Midlife adiposity and the future risk of Parkinson's disease. Neurology 2002 59 7 1051 1057 2-s2.0-0037044236
3. Whitmer R. A., Gunderson E. P., Barrett-Connor E., Quesenberry C. P. Jr., Yaffe K., Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. British Medical Journal 2005 330 7504 1360 1362 2-s2.0-20544462061 10.1136/bmj.38446.466238.E0 (Pubitemid 40839562)
4. Hu G., Jousilahti P., Nissinen A., Antikainen R., Kivipelto M., Tuomilehto J., Body mass index and the risk of Parkinson disease. Neurology 2006 67 11 1955 1959 2-s2.0-33845700948 10.1212/01.wnl.0000247052.18422.e5 (Pubitemid 44967370)
5. Morris J. K., Bomhoff G. L., Stanford J. A., Geiger P. C., Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet. American Journal of Physiology-Regulatory Integrative and Comparative Physiology 2010 299 4 R1082 R1090 2-s2.0-77957575432 10.1152/ajpregu.00449.2010
6. Choi J. Y., Jang E. H., Park C. S., Kang J. H., Enhanced susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in high-fat diet-induced obesity. Free Radical Biology and Medicine 2005 38 6 806 816 2-s2.0-13844275515 10.1016/j.freeradbiomed.2004.12.008 (Pubitemid 40249751)
7. Cano P., Cardinali D. P., Ríos-Lugo M. J., Fernández-Mateos M. P., Reyes Toso C. F., Esquifino A. I., Effect of a high-fat diet on 24-hour pattern of circulating adipocytokines in rats. Obesity 2009 17 10 1866 1871 2-s2.0-70349510462 10.1038/oby.2009.200
8. Gupte A. A., Bomhoff G. L., Swerdlow R. H., Geiger P. C., Heat treatment improves glucose tolerance and prevents skeletal muscle insulin resistance in rats fed a high-fat diet. Diabetes 2009 58 3 567 578 2-s2.0-62749130586 10.2337/db08-1070
9. Uranga R. M., Bruce-Keller A. J., Morrison C. D., Fernandez-Kim S. O., Ebenezer P. J., Zhang L., Dasuri K., Keller J. N., Intersection between metabolic dysfunction, high fat diet consumption, and brain aging. Journal of Neurochemistry 2010 114 2 344 361 2-s2.0-77953835533 10.1111/j.1471-4159.2010. 06803.x
10. Tsuruta R., Fujita M., Ono T., Koda Y., Koga Y., Yamamoto T., Nanba M., Shitara M., Kasaoka S., Maruyama I., Yuasa M., Maekawa T., Hyperglycemia enhances excessive superoxide anion radical generation, oxidative stress, early inflammation, and endothelial injury in forebrain ischemia/reperfusion rats. Brain Research 2010 1309 155 163 2-s2.0-72049126626 10.1016/j.brainres.2009.10. 065
11. Obrosova I. G., Drel V. R., Pacher P., Ilnytska O., Wang Z. Q., Stevens M. J., Yorek M. A., Oxidative-nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy: the relation is revisited. Diabetes 2005 54 12 3435 3441 2-s2.0-33644681565 10.2337/diabetes.54. 12.3435 (Pubitemid 43334333)
12. Szabo C., Multiple pathways of peroxynitrite cytotoxicity. Toxicology Letters 2003 140-141 105 112 2-s2.0-0037432615 10.1016/S0378-4274(02)00507-6 (Pubitemid 36378928)
13. Vincent A. M., Edwards J. L., Sadidi M., Feldman E. L., The antioxidant response as a drug target in diabetic neuropathy. Current Drug Targets 2008 9 1 94 109 2-s2.0-38849162084 10.2174/138945008783431754 (Pubitemid 351201684)
14. Allen D. A., Yaqoob M. M., Harwood S. M., Mechanisms of high glucose-induced apoptosis and its relationship to diabetic complications. Journal of Nutritional Biochemistry 2005 16 12 705 713 2-s2.0-27744509592 10.1016/j.jnutbio.2005.06.007 (Pubitemid 41624792)
15. Tomlinson D. R., Gardiner N. J., Glucose neurotoxicity. Nature Reviews Neuroscience 2008 9 1 36 45 2-s2.0-37349025717 10.1038/nrn2294 (Pubitemid 350295687)
16. Hu G., Jousilahti P., Bidel S., Antikainen R., Tuomilehto J., Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 2007 30 4 842 847 2-s2.0-34147190028 10.2337/dc06-2011 (Pubitemid 46562366)
17. Mercer L. D., Kelly B. L., Horne M. K., Beart P. M., Dietary polyphenols protect dopamine neurons from oxidative insults and apoptosis: investigations in primary rat mesencephalic cultures. Biochemical Pharmacology 2005 69 2 339 345 2-s2.0-13844271390 10.1016/j.bcp.2004.09.018 (Pubitemid 41556580)
18. Pradhan A. D., Manson J. E., Rifai N., Buring J. E., Ridker P. M., C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Journal of the American Medical Association 2001 286 3 327 334 2-s2.0-0035908632 (Pubitemid 32656163)
19. Scigliano G., Musicco M., Soliveri P., Piccolo I., Ronchetti G., Girotti F., Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke 2006 37 5 1184 1188 2-s2.0-33646697974 10.1161/01.STR.0000217384.03237.9c (Pubitemid 43731859)
20. Morano A., Jimenez-Jimenez F. J., Molina J. A., Antolin M. A., Risk-factors for Parkinson's disease: case-control study in the province of Caceres, Spain. Acta Neurologica Scandinavica 1994 89 3 164 170 2-s2.0-0028293630 (Pubitemid 24133430)
21. Simon K. C., Chen H., Schwarzschild M., Ascherio A., Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 2007 69 17 1688 1695 2-s2.0-36048933577 10.1212/01.wnl.0000271883.45010.8a (Pubitemid 350287125)
22. Woo K. S., Chook P., Lolin Y. I., Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997 96 2542 2544 10.1161/01.CIR.96.8.2542 (Pubitemid 27451343)
23. Kruman I. I., Culmsee C., Chan S. L., Kruman Y., Guo Z., Penix L., Mattson M. P., Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. Journal of Neuroscience 2000 20 18 6920 6926 2-s2.0-0034666267
24. Wall R. T., Harlan J. M., Harker L. A., Striker G. E., Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thrombosis Research 1980 18 1-2 113 121 2-s2.0-0018858624 (Pubitemid 10109903)
25. Gomes Trolin C., Regland B., Oreland L., Decreased methionine adenosyltransferase activity in erythrocytes of patients with dementia disorders. European Neuropsychopharmacology 1995 5 2 107 114 2-s2.0-0029058838 10.1016/0924-977X(95)00007-C
26. Blandini F., Fancellu R., Martignoni E., Mangiagalli A., Pacchetti C., Samuele A., Nappi G., Plasma homocysteine and L-DOPA metabolism in patients with Parkinson disease. Clinical Chemistry 2001 47 6 1102 1104 2-s2.0-0035017801 (Pubitemid 32493598)
27. Bottiglieri T., Hyland K., S-adenosylmethionine levels in psychiatric and neurological disorders: a review. Acta Neurologica Scandinavica, Supplementum 1994 89 154 19 26 2-s2.0-0028320572 (Pubitemid 24210859)
28. Loscalzo J., The oxidant stress of hyperhomocyst(e)inemia. The Journal of Clinical Investigation 1996 98 1 5 7 10.1172/JCI118776
29. Kurz K., Frick B., Fürhapter C., Homocysteine metabolism in different human cells. Issues 2013 24
30. Zappacosta B., Mordente A., Persichilli S., Minucci A., Carlino P., Martorana G., Giardina B., De Sole P., Is homocysteine a pro-oxidant? Free Radical Research 2001 35 5 499 505 2-s2.0-0035209718 (Pubitemid 33133586)
31. McGeer P. L., Itagaki S., Boyes B. E., McGeer E. G., Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988 38 8 1285 1291 2-s2.0-0023789193
32. Whitton P. S., Inflammation as a causative factor in the aetiology of Parkinson's disease. British Journal of Pharmacology 2007 150 8 963 976 2-s2.0-34247366072 10.1038/sj.bjp.0707167 (Pubitemid 46628616)
33. Tansey M. G., Frank-Cannon T. C., McCoy M. K., Jae K. L., Martinez T. N., McAlpine F. E., Ruhn K. A., Tran T. A., Neuroinflammation in Parkinson's disease: is there sufficient evidence for mechanism-based interventional therapy? Frontiers in Bioscience 2008 13 2 709 717 2-s2.0-38449109568 10.2741/2713 (Pubitemid 351599776)
34. Mogi M., Harada M., Kondob T., Riederer P., Inagaki H., Minami M., Nagatsu T., Interleukin-1 β interleukin-6, epidermal growth factor and transforming growth factor- α are elevated in the brain from parkinsonian patients. Neuroscience Letters 1994 180 2 147 150 2-s2.0-0028171374 10.1016/0304-3940(94)90508-8
35. Blum-Degena D., Müller T., Kuhn W., Gerlach M., Przuntek H., Riederer P., Interleukin-1 β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neuroscience Letters 1995 202 1-2 17 20 2-s2.0-0029417080 10.1016/0304-3940(95) 12192-7
36. Müller T., Blum-Degen D., Przuntek H., Kuhn W., Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta Neurologica Scandinavica 1998 98 2 142 144 2-s2.0-0031857454 (Pubitemid 28351288)
37. Imai Y., Soda M., Inoue H., Hattori N., Mizuno Y., Takahashi R., An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 2001 105 7 891 902 2-s2.0-0035967883 10.1016/S0092-8674(01)00407-X (Pubitemid 32635090)
38. Imai Y., Soda M., Hatakeyama S., Akagi T., Hashikawa T., Nakayama K., Takahashi R., CHIP is associated with Parkin, a gene responsible for familial Parkinson's Disease, and enhances its ubiquitin ligase activity. Molecular Cell 2002 10 1 55 67 2-s2.0-0036345454 10.1016/S1097-2765(02)00583-X (Pubitemid 34876562)
39. Kaufman R. J., Orchestrating the unfolded protein response in health and disease. Journal of Clinical Investigation 2002 110 10 1389 1398 2-s2.0-0036853914 10.1172/JCI200216886 (Pubitemid 35396907)
40. Imai Y., Soda M., Takahashi R., Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. Journal of Biological Chemistry 2000 275 46 35661 35664 2-s2.0-0034680913 10.1074/jbc.C000447200
41. Bournival J., Quessy P., Martinoli M., Protective effects of resveratrol and quercetin against MPP+ -induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons. Cellular and Molecular Neurobiology 2009 29 8 1169 1180 2-s2.0-77049122576 10.1007/s10571-009-9411-5
42. Whaley-Connell A., McCullough P. A., Sowers J. R., The role of oxidative stress in the metabolic syndrome. Reviews in Cardiovascular Medicine 2011 12 1 21 29 2-s2.0-79957717018 10.3909/ricm0555
43. Zhou C., Huang Y., Przedborski S., Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Annals of the New York Academy of Sciences 2008 1147 93 104 2-s2.0-57649155208 10.1196/annals.1427.023
44. Vincent A. M., Brownlee M., Russell J. W., Oxidative stress and programmed cell death in diabetic neuropathy. Annals of the New York Academy of Sciences 2002 959 368 383 2-s2.0-0036238441 (Pubitemid 34457577)
45. Rolo A. P., Palmeira C. M., Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicology and Applied Pharmacology 2006 212 2 167 178 2-s2.0-33645765312 10.1016/j.taap.2006.01.003
46. Moreira P. I., Santos M. S., Seiça R., Oliveira C. R., Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes. Journal of the Neurological Sciences 2007 257 1-2 206 214 2-s2.0-34249821079 10.1016/j.jns.2007.01.017 (Pubitemid 46856489)
47. Bournival J., Francoeur M. A., Renaud J., Martinoli M. G., Quercetin and sesamin protect neuronal PC12 cells from high-glucose-induced oxidation, nitrosative stress, and apoptosis. Rejuvenation Research 2012 15 3 322 333 10.1089/rej.2011.1242
48. Bureau G., Longpré F., Martinoli M., Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. Journal of Neuroscience Research 2008 86 2 403 410 2-s2.0-38849203188 10.1002/jnr.21503 (Pubitemid 351196745)
49. Gélinas S., Martinoli M., Neuroprotective effect of estradiol and phytoestrogens on MPP+-induced cytotoxicity in neuronal PC12 cells. Journal of Neuroscience Research 2002 70 1 90 96 2-s2.0-0036786068 10.1002/jnr.10315
50. Aruoma O. I., Hayashi Y., Marotta F., Mantello P., Rachmilewitz E., Montagnier L., Applications and bioefficacy of the functional food supplement fermented papaya preparation. Toxicology 2010 278 1 6 16 2-s2.0-78149414013 10.1016/j.tox.2010.09.006
51. Cao H., Qin B., Panickar K. S., Anderson R. A., Tea and cinnamon polyphenols improve the metabolic syndrome. Agro Food Industry Hi-Tech 2008 19 6 14 17 2-s2.0-59649099742
52. García-Arencibia M., González S., de Lago E., Ramos J. A., Mechoulam R., Fernández-Ruiz J., Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Research 2007 1134 1 162 170 2-s2.0-33846401540 10.1016/j.brainres.2006.11.063 (Pubitemid 46135535)
53. Zuardi A. W., Crippa J. A. S., Hallak J. E. C., Pinto J. P., Chagas M. H. N., Rodrigues G. G. R., Dursun S. M., Tumas V., Cannabidiol for the treatment of psychosis in Parkinsons disease. Journal of Psychopharmacology 2009 23 8 979 983 2-s2.0-70449375201 10.1177/0269881108096519
54. Booz G. W., Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radical Biology and Medicine 2011 51 5 1054 1061 2-s2.0-80051664599 10.1016/j.freeradbiomed.2011.01. 007
55. Pacher P., Bátkai S., Kunos G., The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews 2006 58 3 389 462 2-s2.0-33748703859 10.1124/pr.58.3.2 (Pubitemid 44394908)
56. Winquist A., Steenland K., Shankar A., Higher serum uric acid associated with decreased Parkinson's disease prevalence in a large community-based survey. Movement Disorders 2010 25 7 932 936 2-s2.0-77951957859 10.1002/mds.23070
57. Andreadou E., Nikolaou C., Gournaras F., Rentzos M., Boufidou F., Tsoutsou A., Zournas C., Zissimopoulos V., Vassilopoulos D., Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration. Clinical Neurology and Neurosurgery 2009 111 9 724 728 2-s2.0-70349487220 10.1016/j.clineuro.2009.06.012
58. Álvarez-Lario B., Macarrón-vicente J., Is there anything good in uric acid? QJM 2011 104 12 1015 1024 2-s2.0-82855181731 10.1093/qjmed/hcr159 hcr159
59. Chen H., Mosley T. H., Alonso A., Huang X., Plasma urate and Parkinson's disease in the atherosclerosis risk in communities (ARIC) study. American Journal of Epidemiology 2009 169 9 1064 1069 2-s2.0-65249166556 10.1093/aje/kwp033
60. Cucuianu M., Brudasca I., Gout, hyperuricemia and the metabolic syndrome. Revista Româna de Medicina de Laborator 2012 20 3-4
61. Cutler R. G., Antioxidants and aging. American Journal of Clinical Nutrition 1991 53 supplement 1 373S 379S 2-s2.0-0026008160
62. Ames B. N., Cathcart R., Schwiers E., Hochstein P., Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proceedings of the National Academy of Sciences of the United States of America 1981 78 11 6858 6862 2-s2.0-0019787519 (Pubitemid 12216861)
63. Cipriani S., Desjardins C. A., Burdett T. C., Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease. PLoS ONE 2012 7 5 e37331 10.1371/journal.pone.0037331
64. Kamimura N., Nishimaki K., Ohsawa I., Ohta S., Molecular hydrogen improves obesity and diabetes by inducing hepatic FGF21 and stimulating energy metabolism in db/db mice. Obesity 2011 19 7 1396 1403 2-s2.0-79959655309 10.1038/oby.2011.6
65. Huang C. S., Kawamura T., Toyoda Y., Nakao A., Recent advances in hydrogen research as a therapeutic medical gas. Free Radical Research 2010 44 9 971 982 2-s2.0-77956365461 10.3109/10715762.2010.500328
66. Ohsawa I., Nishimaki K., Yamagata K., Ishikawa M., Ohta S., Consumption of hydrogen water prevents atherosclerosis in apolipoprotein E knockout mice. Biochemical and Biophysical Research Communications 2008 377 4 1195 1198 2-s2.0-56349087883 10.1016/j.bbrc.2008.10.156
67. Fukuda K., Asoh S., Ishikawa M., Yamamoto Y., Ohsawa I., Ohta S., Inhalation of hydrogen gas suppresses hepatic injury caused by ischemia/reperfusion through reducing oxidative stress. Biochemical and Biophysical Research Communications 2007 361 3 670 674 2-s2.0-34547768785 10.1016/j.bbrc.2007.07.088 (Pubitemid 47238041)
68. Nakao A., Kaczorowski D. J., Wang Y., Cardinal J. S., Buchholz B. M., Sugimoto R., Tobita K., Lee S., Toyoda Y., Billiar T. R., McCurry K. R., Amelioration of rat cardiac cold ischemia/reperfusion injury with inhaled hydrogen or carbon monoxide, or both. Journal of Heart and Lung Transplantation 2010 29 5 544 553 2-s2.0-77950519281 10.1016/j.healun.2009.10.011
69. Buchholz B. M., Kaczorowski D. J., Sugimoto R., Yang R., Wang Y., Billiar T. R., McCurry K. R., Bauer A. J., Nakao A., Hydrogen inhalation ameliorates oxidative stress in transplantation induced intestinal graft injury. American Journal of Transplantation 2008 8 10 2015 2024 2-s2.0-51849085219 10.1111/j.1600-6143.2008.02359.x
70. Hayashida K., Sano M., Ohsawa I., Shinmura K., Tamaki K., Kimura K., Endo J., Katayama T., Kawamura A., Kohsaka S., Makino S., Ohta S., Ogawa S., Fukuda K., Inhalation of hydrogen gas reduces infarct size in the rat model of myocardial ischemia-reperfusion injury. Biochemical and Biophysical Research Communications 2008 373 1 30 35 2-s2.0-45949085302 10.1016/j.bbrc.2008.05.165
71. Nagata K., Nakashima-Kamimura N., Mikami T., Ohsawa I., Ohta S., Consumption of molecular hydrogen prevents the stress-induced impairments in hippocampus-dependent learning tasks during chronic physical restraint in mice. Neuropsychopharmacology 2009 34 2 501 508 2-s2.0-57849094494 10.1038/npp.2008.95
72. Nakashima-Kamimura N., Mori T., Ohsawa I., Asoh S., Ohta S., Molecular hydrogen alleviates nephrotoxicity induced by an anti-cancer drug cisplatin without compromising anti-tumor activity in mice. Cancer Chemotherapy and Pharmacology 2009 64 4 753 761 2-s2.0-68149136575 10.1007/s00280-008-0924-2
73. Cardinal J. S., Zhan J., Wang Y., Sugimoto R., Tsung A., McCurry K. R., Billiar T. R., Nakao A., Oral hydrogen water prevents chronic allograft nephropathy in rats. Kidney International 2010 77 2 101 109 2-s2.0-73349123786 10.1038/ki.2009.421
74. Fujita K., Seike T., Yutsudo N., Ohno M., Yamada H., Yamaguchi H., Sakumi K., Yamakawa Y., Kido M. A., Takaki A., Katafuchi T., Tanaka Y., Nakabeppu Y., Noda M., Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. PLoS ONE 2009 4 9 2-s2.0-70349705530 10.1371/journal.pone.0007247 e7247
75. Fu Y., Ito M., Fujita Y., Ito M., Ichihara M., Masuda A., Suzuki Y., Maesawa S., Kajita Y., Hirayama M., Ohsawa I., Ohta S., Ohno K., Molecular hydrogen is protective against 6-hydroxydopamine-induced nigrostriatal degeneration in a rat model of Parkinson's disease. Neuroscience Letters 2009 453 2 81 85 2-s2.0-61449159621 10.1016/j.neulet.2009.02.016
76. Ohsawa I., Ishikawa M., Takahashi K., Watanabe M., Nishimaki K., Yamagata K., Katsura K., Katayama Y., Asoh S., Ohta S., Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nature Medicine 2007 13 6 688 694 2-s2.0-34250021071 10.1038/nm1577 (Pubitemid 46889750)
77. Oharazawa H., Igarashi T., Yokota T., Fujii H., Suzuki H., Machide M., Takahashi H., Ohta S., Ohsawa I., Protection of the retina by rapid diffusion of hydrogen: administration of hydrogen-loaded eye drops in retinal ischemia-reperfusion injury. Investigative Ophthalmology and Visual Science 2010 51 1 487 492 2-s2.0-75749117208 10.1167/iovs.09-4089
78. Kajiyama S., Hasegawa G., Asano M., Hosoda H., Fukui M., Nakamura N., Kitawaki J., Imai S., Nakano K., Ohta M., Adachi T., Obayashi H., Yoshikawa T., Supplementation of hydrogen-rich water improves lipid and glucose metabolism in patients with type 2 diabetes or impaired glucose tolerance. Nutrition Research 2008 28 3 137 143 2-s2.0-41349120002 10.1016/j.nutres.2008.01.008 (Pubitemid 351452069)
79. Nakao A., Toyoda Y., Sharma P., Evans M., Guthrie N., Effectiveness of hydrogen rich water on antioxidant status of subjects with potential metabolic syndrome-an open label pilot study. Journal of Clinical Biochemistry and Nutrition 2010 46 2 140 149 2-s2.0-77949869116 10.3164/jcbn.09-100
80. Nakayama M., Kabayama S., Nakano H., Zhu W., Terawaki H., Nakayama K., Katoh K., Satoh T., Ito S., Biological effects of electrolyzed water in hemodialysis. Nephron-Clinical Practice 2009 112 1 c9 c15 2-s2.0-63349111405 10.1159/000210569
81. Suzuki Y., Sano M., Hayashida K., Ohsawa I., Ohta S., Fukuda K., Are the effects of α -glucosidase inhibitors on cardiovascular events related to elevated levels of hydrogen gas in the gastrointestinal tract? FEBS Letters 2009 583 13 2157 2159 2-s2.0-67649321238 10.1016/j.febslet.2009.05.052
82. Ross G. W., Abbott R. D., Petrovitch H., Morens D. M., Grandinetti A., Tung K., Tanner C. M., Masaki K. H., Blanchette P. L., Curb J. D., Popper J. S., White L. R., Association of coffee and caffeine intake with the risk of Parkinson disease. Journal of the American Medical Association 2000 283 20 2674 2679 2-s2.0-0034738134 (Pubitemid 30337329)
83. Nehlig A., Daval J.-L., Debry G., Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Research Reviews 1992 17 2 139 169 2-s2.0-0026730694 10.1016/0165-0173(92)90012-B
84. Popoli P., Caporali M. G., Scotti de Carolis A., Akinesia due to catecholamine depletion in mice is prevented by caffeine. Further evidence for an involvement of adenosinergic system in the control of motility. Journal of Pharmacy and Pharmacology 1991 43 4 280 281 2-s2.0-0025729238
85. Daly J. W., Caffeine analogs: biomedical impact. Cellular and Molecular Life Sciences 2007 64 16 2153 2169 2-s2.0-35248829637 10.1007/s00018-007-7051-9 (Pubitemid 350092417)
86. Devasagayam T. P., Kamat J. P., Mohan H., Kesavan P. C., Caffeine as an antioxidant: inhibition of lipid peroxidation induced by reactive oxygen species. Biochimica et Biophysica Acta 1996 1282 63 70 10.1016/0005-2736(96) 00040-5 (Pubitemid 26189198)
87. Knekt P., Kilkkinen A., Rissanen H., Marniemi J., Sääksjä rvi K., Heliövaara M., Serum vitamin D and the risk of Parkinson disease. Archives of Neurology 2010 67 7 808 811 2-s2.0-77955029222 10.1001/archneurol. 2010.120
88. Buell J. S., Dawson-Hughes B., Vitamin D and neurocognitive dysfunction: preventing "D"ecline? Molecular Aspects of Medicine 2008 29 6 415 422 2-s2.0-56049118465 10.1016/j.mam.2008.05.001
89. Newmark H. L., Newmark J., Vitamin D and Parkinson's disease-a hypothesis. Movement Disorders 2007 22 4 461 468 2-s2.0-34247187985 10.1002/mds.21317 (Pubitemid 46608142)
90. Eyles D. W., Smith S., Kinobe R., Hewison M., McGrath J. J., Distribution of the Vitamin D receptor and 1 α -hydroxylase in human brain. Journal of Chemical Neuroanatomy 2005 29 1 21 30 2-s2.0-10044272155 10.1016/j.jchemneu. 2004.08.006 (Pubitemid 39602785)
91. de Rijk M. C., Breteler M. M., den Breeijen J. H., Dietary antioxidants and Parkinson disease. The Rotterdam study. Archives of Neurology 1997 54 6 762 765 10.1001/archneur.1997.00550180070015
92. Etminan M., Gill S. S., Samii A., Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis. Lancet Neurology 2005 4 6 362 365 2-s2.0-19344362520 10.1016/S1474-4422(05)70097-1 (Pubitemid 40720032)
93. Miller E. R. III, Pastor-Barriuso R., Dalal D., Riemersma R. A., Appel L. J., Guallar E., Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Annals of Internal Medicine 2005 142 1 37 46 2-s2.0-19944427642
94. Erikssen G., Liestøl K., Bjømholt J., Thaulow E., Sandvik L., Mrikssen J., Changes in physical fitness and changes in mortality. The Lancet 1998 352 9130 759 762 2-s2.0-0032487064 (Pubitemid 28404556)
95. Handschin C., Spiegelman B. M., The role of exercise and PGC1 α in inflammation and chronic disease. Nature 2008 454 7203 463 469 2-s2.0-47949104798 10.1038/nature07206
96. Hu F. B., Willett W. C., Li T., Stampfer M. J., Colditz G. A., Manson J. E., Adiposity as compared with physical activity in predicting mortality among women. New England Journal of Medicine 2004 351 26 2694 2703 2-s2.0-10844262691 10.1056/NEJMoa042135 (Pubitemid 39665323)
97. Nieman D. C., Current perspective on exercise immunology. Current Sports Medicine Reports 2003 2 5 239 242 2-s2.0-0242336430
98. Gleeson M., McFarlin B., Flynn M., Exercise and toll-like receptors. Exercise Immunology Review 2006 12 34 53 2-s2.0-33947544182
99. Gleeson M., Immune function in sport and exercise. Journal of Applied Physiology 2007 103 2 693 699 2-s2.0-34547626210 10.1152/japplphysiol.00008.2007 (Pubitemid 47204989)
100. Crizzle A. M., Newhouse I. J., Is physical exercise beneficial for persons with Parkinson's disease? Clinical Journal of Sport Medicine 2006 16 5 422 425 2-s2.0-33749452201 10.1097/01.jsm.0000244612.55550.7d (Pubitemid 44511458)
101. Reuter I., Engelhardt M., Stecker K., Baas H., Therapeutic value of exercise training in Parkinson's disease. Medicine and Science in Sports and Exercise 1999 31 11 1544 1549 2-s2.0-0032757596
102. Palmer S. S., Mortimer J. A., Webster D. D., Exercise therapy for Parkinson's disease. Archives of Physical Medicine and Rehabilitation 1986 67 10 741 745 2-s2.0-0022442734 (Pubitemid 16002528)